Liva Nova PLC LIVN
We take great care to ensure that the data presented and summarized in this overview for LivaNova PLC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LIVN
View all-
Black Rock Inc. New York, NY7.35MShares$394 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA5.94MShares$318 Million0.25% of portfolio
-
Barrow Hanley Mewhinney & Strauss LLC Dallas, TX2.36MShares$126 Million0.47% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.28MShares$122 Million0.06% of portfolio
-
State Street Corp Boston, MA2MShares$107 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$98.2 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.48MShares$79.4 Million0.02% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.45MShares$77.8 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.38MShares$73.8 Million0.02% of portfolio
-
Barclays PLC London, X01.36MShares$72.7 Million0.03% of portfolio
Latest Institutional Activity in LIVN
Top Purchases
Top Sells
About LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Insider Transactions at LIVN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 15
2024
|
Brooke Story Director |
SELL
Payment of exercise price or tax liability
|
Direct |
584
-14.38%
|
$30,368
$52.68 P/Share
|
Jun 15
2024
|
Brooke Story Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+39.76%
|
-
|
Jun 15
2024
|
Sharon O'Kane Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,260
-11.72%
|
$65,520
$52.68 P/Share
|
Jun 15
2024
|
Sharon O'Kane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+19.95%
|
-
|
Jun 15
2024
|
Todd C Schermerhorn Director |
SELL
Payment of exercise price or tax liability
|
Direct |
586
-8.82%
|
$30,472
$52.68 P/Share
|
Jun 15
2024
|
Todd C Schermerhorn Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+28.75%
|
-
|
Jun 15
2024
|
Francesco Bianchi Director |
SELL
Payment of exercise price or tax liability
|
Direct |
585
-5.39%
|
$30,420
$52.68 P/Share
|
Jun 15
2024
|
Francesco Bianchi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+19.8%
|
-
|
Jun 15
2024
|
Alex Shvartsburg CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
670
-3.45%
|
$34,840
$52.68 P/Share
|
Jun 15
2024
|
Alex Shvartsburg CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,576
+7.51%
|
-
|
Jun 15
2024
|
Seng Stacy Enxing Director |
SELL
Payment of exercise price or tax liability
|
Direct |
585
-6.27%
|
$30,420
$52.68 P/Share
|
Jun 15
2024
|
Seng Stacy Enxing Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+22.31%
|
-
|
Jun 15
2024
|
Peter M Wilver Director |
SELL
Payment of exercise price or tax liability
|
Direct |
585
-13.55%
|
$30,420
$52.68 P/Share
|
Jun 15
2024
|
Peter M Wilver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+38.3%
|
-
|
Jun 03
2024
|
Daniel Jeffrey Moore Director |
SELL
Open market or private sale
|
Direct |
56,623
-35.88%
|
$3,397,380
$60.59 P/Share
|
Jun 03
2024
|
Daniel Jeffrey Moore Director |
BUY
Exercise of conversion of derivative security
|
Direct |
56,623
+40.22%
|
$3,227,511
$57.39 P/Share
|
Mar 30
2024
|
Alex Shvartsburg CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,310
-26.15%
|
$347,050
$55.94 P/Share
|
Mar 30
2024
|
Alex Shvartsburg CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,752
+37.94%
|
-
|
Mar 30
2024
|
Trui Hebbelinck Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,541
-28.68%
|
$304,755
$55.94 P/Share
|
Mar 30
2024
|
Trui Hebbelinck Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,779
+37.88%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 141K shares |
---|
Payment of exercise price or tax liability | 31.4K shares |
---|---|
Open market or private sale | 56.6K shares |